Rising Insulin Prices Highlight SPT Week in Review

5. FDA Approves Ibrutinib Combo Regimen for CLL

Ibrutinub plus obinutuzumab is the first FDA-approved non-chemotherapy combination regimen for chronic lymphocytic lymphoma and small lymphocytic lymphoma. Read more.

4. Targeted Approach Shows Promise in Treating Deadly Pediatric Brain Cancer

A targeted therapeutic approach shrank tumors caused by medulloblastoma, a deadly form a pediatric brain cancer. Read more.

3. Resource-based Approach to Pre-ART CD4 Testing Can Significantly Reduce HIV-related Mortality

Better strategies are needed to adequately identify and prevent opportunistic infections and related deaths in patients with advanced HIV. Read more.

2. Driven by Surging Prices, Patient Spend on Insulin Nearly Doubles Over 5 Years

Analysis shows prices among all insulin types and products increased steadily between 2012 and 2016. Read more.

1. Senate Hearing on Drug Prices Addresses Skyrocketing Insulin Costs

Senate Finance Committee Chairman Senator Charles Grassley pledged to “get to the bottom of the insulin price problem.” Read more.